Publication
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.
Maria-Cynthia Fuentes-Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta
The FEBS journalSep 1, 2026PMID 42165697doi:10.1111/febs.70599 PMC13534934Journal ArticleReviewpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260909-000004
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide in combination with proteasome inhibitors, dexamethasone and anti-CD38 monoclonal antibodies, play a central role in the treatment of multiple myeloma (MM) across newly diagnosed and relapsed stages. These treatment regimens…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.